Seminars in Nuclear Medicine
Volume 36, Issue 3 , Pages 248-256 , July 2006

The Role of Positron Emission Tomography in the Management of Pancreatic Cancer

  • Farrokh Pakzad, MRCS
    • ,
  • Ashley M. Groves, MD, FRCR
    • ,
  • Peter J. Ell, FMedSci, Dr HC, AΩA

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Peter J. Ell, FMedSci, Dr HC, AΩA, The Institute of Nuclear Medicine–UCL, University College London Hospitals NHS Trust, 235 Euston Road, London NW1 2BU, United Kingdom

References 

  1. Gold EB , Goldin SB . Epidemiology of and risk factors for pancreatic cancer . Surg Oncol Clin N Am . 1998;7:67–91
  2. Heuch I , Kvale G , Jacobsen BK , et al.   Use of alcohol, tobacco and coffee, and risk of pancreatic cancer . Br J Cancer . 1983;48:637–643
  3. Li D , Xie K , Wolff R , Abbruzzese JL . Pancreatic cancer . Lancet 27; . 2004;363(9414):1049–1057
  4. DiMagno EP . Pancreatic cancer (clinical presentation, pitfalls and early clues) . Ann Oncol . 1999;10(suppl 4):140–142
  5. Takhar AS , Palaniappan P , Dhingsa R , et al.   Recent developments in diagnosis of pancreatic cancer . BMJ 18; . 2004;329:668–673
  6. Saruc M , Pour PM . Diabetes and its relationship to pancreatic carcinoma . Pancreas . 2003;26:381–387
  7. Bluemke DA , Abrams RA , Yeo CJ , et al.   Recurrent pancreatic adenocarcinoma (spiral CT evaluation following the Whipple procedure) . Radiographics . 1997;17:303–313
  8. Ozkan H , Kaya M , Cengiz A . Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer . Hepatogastroenterology . 2003;50:1669–1674
  9. Willett CG , Daly WJ , Warshaw AL . CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer . Am J Surg . 1996;172:350–352
  10. Yeo TP , Hruban RH , Leach SD , et al.   Pancreatic cancer . Curr Probl Cancer . 2002;26:176–275
  11. Minniti S , Bruno C , Biasiutti C , et al.   Sonography versus helical CT in identification and staging of pancreatic ductal adenocarcinoma . J Clin Ultrasound . 2003;31:175–182
  12. Clarke DL , Thomson SR , Madiba TE , et al.   Preoperative imaging of pancreatic cancer (a management-oriented approach) . J Am Coll Surg . 2003;196:119–129
  13. Haycox A , Lombard M , Neoptolemos J , et al.   Review article (current practice and future perspectives in detection and diagnosis of pancreatic cancer) . Aliment Pharmacol Ther . 1998;12:937–948
  14. Rickes S , Unkrodt K , Neye H , et al.   Differentiation of pancreatic tumours by conventional ultrasound, unenhanced and echo-enhanced power Doppler sonography . Scand J Gastroenterol . 2002;11:1313–1320
  15. Kitano M , Kudo M , Maekawa K , et al.   Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography . Gut . 2004;53:854–859
  16. Smith SL , Rajan PS . Imaging of pancreatic adenocarcinoma with emphasis on multidetector CT . Clin Radiol . 2004;59:26–38
  17. Fuhrman GM , Charnsangavej C , Abbruzzese JL , et al.   Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms . Am J Surg . 1994;167:104–111 discussion 111-103
  18. Adamek HE , Albert J , Breer H , et al.   Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography (a prospective controlled study) . Lancet 15; . 2000;356:190–193
  19. Hanbidge AE . Cancer of the pancreas (the best image for early detection—CT, MRI, PET or US?) . Can J Gastroenterol . 2002;16:101–105
  20. Conio M , Demarquay JF , De Luca L , et al.   Endoscopic treatment of pancreatico-biliary malignancies . Crit Rev Oncol Hematol . 2001;37:127–135
  21. Graham RA , Bankoff M , Hediger R , et al.   Fine-needle aspiration biopsy of pancreatic ductal adenocarcinoma (loss of diagnostic accuracy with small tumors) . J Surg Oncol . 1994;55:92–94
  22. Mariani A . Pharmacological prevention of post-ERCP pancreatitis (which therapy is best?) . JOP . 2003;4:68–74
  23. Fung AS , Tsiotos GG , Sarr MG . ERCP-induced acute necrotizing pancreatitis (is it a more severe disease?) . Pancreas . 1997;15:217–221
  24. Mertz HR , Sechopoulos P , Delbeke D , et al.   EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma . Gastrointest Endosc . 2000;52:367–371
  25. Berberat P , Friess H , Kashiwagi M , et al.   Diagnosis and staging of pancreatic cancer by positron emission tomography . World J Surg . 1999;23:882–887
  26. Higashi T , Tamaki N , Honda T , et al.   Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study . J Nucl Med . 1997;38:1337–1344
  27. Reske SN , Grillenberger KG , Glatting G , et al.   Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma . J Nucl Med . 1997;38:1344–1348
  28. Zimny M , Bares R , Fass J , et al.   Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma (a report of 106 cases) . Eur J Nucl Med . 1997;24:678–682
  29. Inokuma T , Tamaki N , Torizuka T , et al.   Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose (comparison with CT and US) . Radiology . 1995;195:345–352
  30. Koyama K , Okamura T , Kawabe J , et al.   Diagnostic usefulness of FDG PET for pancreatic mass lesions . Ann Nucl Med . 2001;15:217–224
  31. Rose DM , Delbeke D , Beauchamp RD , et al.   18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer . Ann Surg . 1999;229:729–737 discussion 737-728
  32. Sperti C , Pasquali C , Decet G , et al.   F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts (a prospective study) . J Gastrointest Surg . 2005;9:22–28 discussion 28-29
  33. Nakamoto Y , Higashi T , Sakahara H , et al.   Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas . Cancer . 2000;89:2547–2554
  34. Gambhir SS , Czernin J , Schwimmer J , et al.   A tabulated summary of the FDG PET literature . J Nucl Med . 2001;42(suppl 5):1S–93S
  35. Bares R , Dohmen BM , Cremerius U , et al.   [Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma] . Radiologe . 1996;36:435–440
  36. Bares R , Klever P , Hauptmann S , et al.   F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer . Radiology . 1994;192:79–86
  37. Diederichs CG , Staib L , Vogel J , et al.   Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses . Pancreas . 2000;20:109–116
  38. Frohlich A , Diederichs CG , Staib L , et al.   Detection of liver metastases from pancreatic cancer using FDG PET . J Nucl Med . 1999;40:250–255
  39. Lim JE , Chien MW , Earle CC . Prognostic factors following curative resection for pancreatic adenocarcinoma (a population-based, linked database analysis of 396 patients) . Ann Surg . 2003;237:74–85
  40. Wittekind C , Compton CC , Greene FL , et al.   TNM residual tumor classification revisited . Cancer . 2002;94:2511–2516
  41. Sperti C , Pasquali C , Catalini S , et al.   CA 19-9 as a prognostic index after resection for pancreatic cancer . J Surg Oncol . 1993;52:137–141
  42. Vogel I , Kalthoff H , Henne-Bruns D , et al.   Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma . Pancreatology . 2002;2:79–88
  43. Nakata B , Nishimura S , Ishikawa T , et al.   Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer . Int J Oncol . 2001;19:53–58
  44. Sperti C , Pasquali C , Chierichetti F , et al.   18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma . J Gastrointest Surg . 2003;7:953–959 discussion 959-960
  45. Maisey NR , Webb A , Flux GD , et al.   FDG-PET in the prediction of survival of patients with cancer of the pancreas (a pilot study) . Br J Cancer . 2000;83:287–293
  46. Okada J , Yoshikawa K , Itami M , et al.   Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma (a comparison with proliferative activity) . J Nucl Med . 1992;33:325–329
  47. Francis DL , Freeman A , Visvikis D , et al.   In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography . Gut . 2003;11:1602–1606
  48. Buck AC , Schirrmeister HH , Guhlmann CA , et al.   Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis (does in vivo FDG uptake correlate with proliferative activity?) . J Nucl Med . 2001;42:721–725
  49. Ruf J , Lopez Hanninen E , Oettle H , et al.   Detection of recurrent pancreatic cancer (comparison of FDG-PET with CT/MRI) . Pancreatology . 2005;5:266–272
  50. Shreve PD . Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease . Eur J Nucl Med . 1998;25:259–264
  51. Lemke AJ , Niehues SM , Hosten N , et al.   Retrospective digital image fusion of multidetector CT and 18F-FDG PET (clinical value in pancreatic lesions–a prospective study with 104 patients) . J Nucl Med . 2004;45:1279–1286
  52. Heinrich S , Goerres GW , Schafer M , et al.   Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness . Ann Surg . 2005;242:235–243

PII: S0001-2998(06)00019-5

doi: 10.1053/j.semnuclmed.2006.03.005

Seminars in Nuclear Medicine
Volume 36, Issue 3 , Pages 248-256 , July 2006

Article Tools

* Image Usage & Resolution